Application of an Open‐Source Modular Framework for Pharmacokinetic, Pharmacodynamic, and Safety Simulations to Anti‐Tuberculosis Drugs
CPT: Pharmacometrics & Systems Pharmacology · 2026
DOI: 10.1002/psp4.70347 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Marco Siccardi und 9 weiteren Autor:innen. Beteiligte Einrichtung: ESQlabs GmbH, Saterland, Germany. Hauptthemen laut MEDLINE: Antitubercular Agents, Models, Biological, Tuberculosis. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tuberculosis (TB) treatment requires long‐term multidrug regimens where dosing, efficacy, and safety optimization remain challenging. This tutorial establishes an integrated, open‐source, modular framework connecting high‐throughput PBPK (HT‐PBPK) simulations, mechanistic PBPK models, pharmacodynamic endpoints, and safety predictions for anti‐TB drugs. Using the Open Systems Pharmacology Suite and ESQhtpbpk (R package), physicochemical parameters were obtained from literature, with QSAR‐predicted values supplementing missing experimental data to generate generic PBPK models. Mechanistic models were parameterized for moxidectin, isoniazid, moxifloxacin, bedaquiline, and rifampicin. A quantitative TB disease model of host‐pathogen dynamics and PK‐PD interactions was integrated to assess efficacy. A cardiac electrophysiology model incorporating ion channel inhibition data was coupled with PBPK predictions for moxifloxacin and bedaquiline. The HT‐PBPK framework automated virtual studies across compounds and dosing regimens. Mechanistic models reproduced systemic and local disposition within two‐fold of the observed data. The TB disease model predicted treatment response across exposure scenarios. The cardiac module captured the dose‐QTc relationship for moxifloxacin and identified metabolite‐driven QTc prolongation with bedaquiline, consistent with clinical observations. This open‐source, modular framework spans compound screening, mechanistic PK, efficacy, and cardiotoxicity, providing a reproducible tool to support TB drug development, guide dose selection, and inform regulatory decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ESQlabs GmbH, Saterland, Germany.
- University of Liverpool, Liverpool, UK.
ORCID-Profile: Nina Nauwelaerts, Raphaëlle Lesage, Vanessa Baier, Miao-Chan Huang, Alexander Kulesza, Stephan Schaller
Zitieren
APA
Siccardi, M., Nauwelaerts, N., Lesage, R., Lefaudeux, D., Baier, V., Karamitsou, V., Demeester, C., Huang, M. C., Kulesza, A., & Schaller, S. (2026). Application of an Open‐Source Modular Framework for Pharmacokinetic, Pharmacodynamic, and Safety Simulations to Anti‐Tuberculosis Drugs. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70347
Vancouver
Siccardi M, Nauwelaerts N, Lesage R, Lefaudeux D, Baier V, Karamitsou V, et al. Application of an Open‐Source Modular Framework for Pharmacokinetic, Pharmacodynamic, and Safety Simulations to Anti‐Tuberculosis Drugs. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70347
BibTeX
@article{Siccardi2026,
author = {Siccardi, Marco and Nauwelaerts, Nina and Lesage, Raphaëlle and Lefaudeux, Diane and Baier, Vanessa and Karamitsou, Venetia and Demeester, Cleo and Huang, Miao-Chan and Kulesza, Alexander and Schaller, Stephan},
title = {Application of an Open‐Source Modular Framework for Pharmacokinetic, Pharmacodynamic, and Safety Simulations to Anti‐Tuberculosis Drugs},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
doi = {10.1002/psp4.70347}
}
EUVIMED